<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="1 [1], Mellen Center for Multiple Sclerosis Treatment and Research," exact="Cleveland Clinic" post="Cleveland OH USA Correspondence: Mary Rensel Mellen Center for"/>
 <result pre="Mary Rensel Mellen Center for Multiple Sclerosis Treatment and Research," exact="Cleveland Clinic," post="9500 Euclid Ave. U10, Cleveland, OH 44195, USA Tel"/>
 <result pre="safety, and tolerability of fingolimod. Currently, fingolimod is the only" exact="Food and Drug Administration" post="and European Medicines Agency approved disease-modifying therapy to treat"/>
 <result pre="considered as standard first-line DMTs in POMS despite lack of" exact="Food and Drug Administration" post="(FDA) approval specifically for POMS. They have been shown"/>
 <result pre="funding via a Sylvia Lawry Physician Fellowship Grant through the" exact="National Multiple Sclerosis Society" post="(#FP-1707-28-768), and has received personal fees for speaking for"/>
 <result pre="via a Sylvia Lawry Physician Fellowship Grant through the National" exact="Multiple Sclerosis Society" post="(#FP-1707-28-768), and has received personal fees for speaking for"/>
 <result pre="for Serono and Biogen, received consulting fees from Biogen, Teva," exact="Genzyme" post="and Novartis, commercial research support from Medimmune and Genentech,"/>
 <result pre="support from Medimmune and Genentech, foundation/society research support from the" exact="National Multiple Sclerosis Society," post="and educational grants from Genzyme. She is on speaker’s"/>
 <result pre="from Medimmune and Genentech, foundation/society research support from the National" exact="Multiple Sclerosis Society," post="and educational grants from Genzyme. She is on speaker’s"/>
</results>
